ArticleDiscover oncology2025
RNA methylated long non-coding RNAs as potential biomarkers for prognosis prediction in patients with lung adenocarcinoma: development of a risk assessment model.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionLung adenocarcinoma (LUAD) is the most prevalent form of lung cancer worldwide. Long non-coding RNA (lncRNAs) are non-protein coding RNAs that are involved in lung cancer. This study aimed to develop a lncRNA-based risk assessment model based on RNA methylation to evaluate the prognosis of patients with LUAD.
methodThe TCGA-LUAD dataset consisted of 524 primary tumor samples and 59 normal samples, and the validation set (GSE3121011), which included 246 patients with LUAD, was used for this analysis.Pearson's correlation analysis was used to identify lncRNAs associated with RNA methylation in LUAD. Univariate, least absolute shrinkage and selection operators, and multivariate Cox analyses were used to construct the prognostic model. Gene oncology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were used to identify enriched biological processes. Gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) were used to visualize the dataset and gene set variation analyses. Kaplan-Meier and decision curve analyses were used to assess the accuracy. qRT-PCR was used to verify the expression of lncRNAs. Invasion and cell scratch assays were conducted to evaluate migration capacity, and colony formation experiments were performed to assess proliferation ability.
resultTen RNA methylation-associated lncRNAs were identified to construct risk features. According to the risk model, the patients were categorized into low- and high-risk groups, with the latter exhibiting a less favorable prognosis. The expression levels of the lncRNAs exceeded those in lung epithelial cells. After siRNA transfection, the proliferation and migration abilities of the tumor cells were significantly reduced. The risk-scoring model may be a potential indicator for predicting the sensitivity of patients with LUAD to immunotherapy.
conclusionThe model constructed in this study can accurately predict the prognosis of patients with LUAD, and holds promise for future immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.